Corrigendum: “Chemokine/cytokine profiling after rituximab: Reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS” (Cytokine (2011) 53 (384–389) (S1043466610007751) (10.1016/j.cyto.2010.12.004));Chemokine/cytokine profiling after rituximab: Reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS

Cytokine

Volumn 53, Issue 3, 2011, Pages 384-389

  Pranzatelli, Michael R ^a   Tate, Elizabeth D ^a   Travelstead, Anna L ^a   Verhulst, Steven J ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A proliferation inducing ligand; ACTH; B cell activating factor; B cell repopulation; Paraneoplastic syndrome

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; CHEMOKINE; CORTICOTROPIN; CXCL13 CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 6; RITUXIMAB;

ADJUVANT THERAPY; ARTICLE; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; OPSOCLONUS MYOCLONUS SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 79251640439     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.07.011     Document Type: Erratum

References (32)

1. Mackay F., Silveira P.A., Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007, 19:327-336.
2. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006, 59:880-892.
3. Day E.S., Cachero T.G., Qian F., Sun Y., Wen D., Pelletier M., et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005, 44:1919-1931.
4. Pranzatelli M.R., Travelstead A., Tate E.D., Allison T.J., Moticka E.J., Franz D.N., et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology 2004, 62:1526-1532.
5. de Graaf M., de Beukelaar J., Bergsma J., Kraan J., van den Bent M., Klimek M., et al. B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol 2008, 195:164-170.
6. Pranzatelli M.R., Tate E.D., Travelstead A.L., Barbosa J., Bergamini R.A., Civitello L., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006, 28:585-593.
7. Pranzatelli M.R., Tate E.D., Travelstead A.L., Colliver J.A. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol 2010, 30:106-113.
8. Pranzatelli M.R., Tate E.D., Verhulst S.J., Bertolone S.J., Bhatla D., Granger M., et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2010, 32(5):e167-e172.
9. Szodoray P., Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjo{double acute}gren's syndrome. Scand J Immunol 2005, 62:421-428.
10. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjo{double acute}gren's syndrome. Ann Rheum Dis 2007, 66:351-357.
11. Vallerskog T., Heimbürger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Arthritis Res Ther 2006, 8:R167.
12. Toubi E., Kessel A., Slobodin G., Boulman N., Pavlotzky E., Zisman D., et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:818-820.
13. Bergamin F., Vincent I.E., Summerfield A., McCullough K.C. Essential role of antigen-presenting cell-derived BAFF for antibody responses. Eur J Immunol 2007, 37:3122-3130.
14. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
15. Langat D.L., Wheaton D.A., Platt J.S., Sifers T., Hunt J.S. Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta. Am J Pathol 2008, 172:1303-1311.
16. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 2003, 62:ii25-ii27.
17. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005, 1050:34-39.
18. Pranzatelli M.R., Tate E.D., Hoefgen E.R., Swan J.A., Colliver J.A. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine 2008, 44:26-32.
19. Emmerich F., Bal G., Barakat A., Milz J., Mühle C., Martinez-Gamboa L., et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2006, 136:309-314.
20. Fabris M., Visentini D., De Re V., Picierno A., Maieron R., Cannizzaro R., et al. Elevated B cell-activating factor of the tumour necrosis factor family in celiac disease. Scand J Gastroenterol 2007, 42:1434-1439.
21. Kang J.S., Yoon Y.D., Ahn J.H., Kim S.C., Kim K.H., Kim H.M., et al. B cell-activating factor is a novel diagnosis parameter for asthma. Int Arch Allergy Immunol 2006, 141:181-188.
22. Krumbholz M., Specks U., Wick M., Kalled S.L., Jenne D., Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005, 25:298-302.
23. Sarantopoulos S., Stevenson K.E., Kim H.T., Bhuiya N.S., Cutler C.S., Soiffer R.J., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007, 13:6107-6114.
24. Yang M., Hase H., Legarda-Addison D., Varughese L., Seed B., Ting A.T. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol 2005, 175:2814-2824.
25. Chu V.T., Enghard P., Riemekasten G., Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol 2007, 179:5947-5957.
26. Ng L.G., Sutherland A.P., Newton R., Qian F., Cachero T.G., Scott M.L., et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004, 173:807-817.
27. Thompson J.S., Schneider P., Kalled S.L., Wang L., Lefevre E.A., Cachero T.G., et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000, 192:129-135.
28. Lee H.T., Shiao Y.M., Wu T.H., Chen W.S., Hsu Y.H., Tsai S.F., et al. Serum BCL/CXCL13 concentrations and renal expression of CXCL13/CXCL15 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 2010, 37:45-52.
29. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjo{double acute}gren's syndrome. Arthritis Rheum 2007, 56:1464-1477.
30. Meraouna A., Cizeron-Clairac G., Panse R.L., Bismuth J., Truffault F., Tallaksen C., et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006, 108:432-440.
31. Carlsen H.S., Baekkevold E.S., Morton H.C., Haraldsen G., Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 2004, 104:3021-3027.
32. Maier L.M., Anderson D.E., Severson C.A., Baecher-Allan C., Healy B., Liu D.V., et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009, 182:1541-1547.